GlassScriptPhysician profile
Lisa Catherine Kugelman
NPI 1235173873
$3,330.20
in general payments reported to CMS, 2019-2025
23 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2021: $59.36 · 2022: $289 · 2023: $460 · 2024: $1,111 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.29 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $536.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $509.63 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $328.01 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $194.66 | 2022-2025 | |
| Janssen Biotech, INC. | $188.66 | 2025 | Tremfya |
| Amgen INC. | $187.75 | 2023-2024 | Otezla |
| Ucb, INC. | $182.36 | 2021-2024 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $179.98 | 2024-2025 | |
| Leo Pharma INC. | $147.78 | 2022-2025 | Adbry, Anzupgo |
| Dermira, INC. | $124.45 | 2019 | |
| Janssen Scientific Affairs, LLC | $122.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $102.72 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $101.60 | 2019-2025 | Cabtreo, Jublia |
| Lilly USA, LLC | $91.67 | 2022-2024 | Ebglyss, Olumiant, Taltz |
| Incyte Corporation | $86.25 | 2022-2024 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $66.76 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $37.07 | 2019-2025 | Nemluvio |
| Organon LLC | $34.77 | 2025 | |
| Dermavant Sciences, INC. | $26.21 | 2023 | Vtama |
| Botanix Sb INC | $23.97 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $23.41 | 2023 | |
| Pfizer INC. | $22.03 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Kugelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.